Azam Ahmad T, Odeyinka Oladipo, Alhashimi Rasha, Thoota Sankeerth, Ashok Tejaswini, Palyam Vishnu, Sange Ibrahim
Internal Medicine, Allama Iqbal Medical College, Lahore, PAK.
Internal Medicine, University of Ibadan College of Medicine, Ibadan, NGA.
Cureus. 2022 Feb 18;14(2):e22367. doi: 10.7759/cureus.22367. eCollection 2022 Feb.
Rheumatoid arthritis (RA) is a prevalent autoimmune disorder affecting 0.5-1% of the population in North America and Europe. Pulmonary manifestations in rheumatoid arthritis patients result in significant morbidity and mortality. Management of these pulmonary manifestations in RA patients causes various challenges for the physicians. This review article has discussed the current state of knowledge of these pulmonary manifestations, including interstitial lung diseases, airway-related diseases, pulmonary vasculature, and pleural involvement in RA patients. This review article has also explored various pharmacological options, including steroids, disease-modifying antirheumatic drugs (DMARDs), immunosuppressive drugs, and biologic agents. Non-pharmacological options include conservative treatment, supplemental oxygen, pulmonary rehabilitation, smoking cessation, and lung transplantation.
类风湿关节炎（RA）是一种常见的自身免疫性疾病，在北美和欧洲影响着0.5%-1%的人口。类风湿关节炎患者的肺部表现会导致显著的发病率和死亡率。对这些类风湿关节炎患者肺部表现的管理给医生带来了各种挑战。这篇综述文章讨论了这些肺部表现的当前知识状态，包括间质性肺疾病、气道相关疾病、肺血管系统以及类风湿关节炎患者的胸膜受累情况。这篇综述文章还探讨了各种药物治疗选择，包括类固醇、改善病情抗风湿药（DMARDs）、免疫抑制药物和生物制剂。非药物治疗选择包括保守治疗、补充氧气、肺康复、戒烟和肺移植。
